#flashcards 
1.  intestinal and hepatic first pass metabolism by metabolic enzymes may decrease [[Oral (口服用藥)|oral]] [[bioavailability]] ​
2.  intestinal [[P-glycoprotein]] (efflux transporter) may decrease drug absorption
---
## Intestinal first pass metabolism
1. CYP3A4 is rich in mucosal enterocytes of the small intestinal villi​
2. CYP3A4 substrates (drugs, foods or herbs):  
	- low and variable [[bioavailability]]; terfenadine​
3. CYP3A4 substrate interactions with inducer or inhibitor (drugs; foods; herbs).​
	- CYP3A4 inducer – =={{dexamethasone}}== ​
	- CYP3A4 inhibitors – =={{erythromycin}}==, =={{grape fruit juice}}==, =={{ketoconazole}}==
4. ketoconazole interaction with {{terfenadine}}
---
## P-Glycoprotein (P-gp)​
1. efflux transporter
2. [[P-glycoprotein|P-gp]] substrates: low [[Oral (口服用藥)|oral]] [[bioavailability]], 
	- eg. {{digoxin}}, {{cyclosporin}}, {{etoposide}}, {{vinblastine}}, {{taxol}}, {{loperamide}}​
3. [[P-glycoprotein|P-gp]] inhibitors: 
	- {{quinidine}}, {{ketoconazole}} {{grapefruit juice}}
4. [[P-glycoprotein|P-gp]] inducers:
	- {{dexamethasone}}, {{prazosin}}​
5.  drug interaction of digoxin and quinidine
<!--SR:!2023-03-22,1,230!2023-03-25,4,270!2023-03-25,4,270!2023-03-25,4,270!2023-03-22,1,230-->